Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Abington Memorial Hospital
mi
from
Abington, PA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Women and Infants Hospital
mi
from
Providence, RI
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Saint Francis Hospital
mi
from
Greenville, SC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Saint Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Biomarkers for Gynecologic Cancer
Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population
Status: Enrolling
Updated:  1/29/2018
Ohio State University
mi
from
Columbus, OH
Biomarkers for Gynecologic Cancer
Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population
Status: Enrolling
Updated: 1/29/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma
Status: Enrolling
Updated:  2/1/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma
Status: Enrolling
Updated: 2/1/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated:  2/2/2018
Brookdale Hospital and Medical Center
mi
from
Brooklyn, NY
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated: 2/2/2018
Brookdale Hospital and Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated:  2/2/2018
Texas Tech Health Sciences Center
mi
from
El Paso, TX
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated: 2/2/2018
Texas Tech Health Sciences Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated:  2/2/2018
Vancouver General Hospital - Women's Clinic (G&L Diamond Centre)
mi
from
Vancouver,
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.
Status: Enrolling
Updated: 2/2/2018
Vancouver General Hospital - Women's Clinic (G&L Diamond Centre)
mi
from
Vancouver,
Click here to add this to my saved trials
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
Status: Enrolling
Updated:  2/7/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
Status: Enrolling
Updated: 2/7/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Beebe Medical Center
mi
from
Lewes, DE
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Northwest Hospital
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Northwest Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Pacific Gynecology Specialists
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
University of Washington Medical Center
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Women and Infants Hospital
mi
from
Providence, RI
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Union Hospital of Cecil County
mi
from
Elkton, MD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sanford NCI Community Oncology Research Program of the North Central Plains
mi
from
Sioux Falls, SD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sanford NCI Community Oncology Research Program of the North Central Plains
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated:  2/15/2018
Integrated Community Oncology Network at Southside Cancer Center
mi
from
Jacksonville, FL
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated: 2/15/2018
Integrated Community Oncology Network at Southside Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated:  2/15/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated: 2/15/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated:  2/15/2018
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated: 2/15/2018
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated:  2/15/2018
Summa Barberton Hospital
mi
from
Barberton, OH
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer
Status: Enrolling
Updated: 2/15/2018
Summa Barberton Hospital
mi
from
Barberton, OH
Click here to add this to my saved trials